NASDAQ: AMLXAmylyx Pharmaceuticals Inc Stock
$11.87-0.44 (-3.57%)
Updated Dec 17, 2025
AMLX Price
$11.87
Fair Value Price
-$6.66
Market Cap
$1.30B
52 Week Low
$2.60
52 Week High
$16.96
P/E
-6.63x
P/B
3.93x
P/S
-1,906.03x
PEG
N/A
Dividend Yield
N/A
Revenue
-$665.00k
Earnings
-$149.28M
Gross Margin
100%
Operating Margin
22,543.91%
Profit Margin
22,448.4%
Debt to Equity
0.09
Operating Cash Flow
-$154M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AMLX Overview
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, for the treatment of ALS. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AMLX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AMLX
Ranked#265 of 488
Ranked#265 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.05 | A | |
| $306.05 | A | |
| $7.13 | A |
Be the first to know about important AMLX news, forecast changes, insider trades & much more!
AMLX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMLX ($11.87) is overvalued by 278.21% relative to our estimate of its Fair Value price of -$6.66 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AMLX ($11.87) is not significantly undervalued (278.21%) relative to our estimate of its Fair Value price of -$6.66 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMLX due diligence checks available for Premium users.
Valuation
AMLX fair value
Fair Value of AMLX stock based on Discounted Cash Flow (DCF)
Price
$11.87
Fair Value
-$6.66
Undervalued by
278.21%
AMLX ($11.87) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMLX ($11.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.63x
Industry
152.67x
Market
43.93x
AMLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.93x
Industry
5.19x
AMLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMLX's financial health
Profit margin
Revenue
$0.0
Net Income
-$34.4M
Profit Margin
0%
AMLX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AMLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$362.7M
Liabilities
$30.7M
Debt to equity
0.09
AMLX's short-term assets ($353.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMLX's short-term assets ($353.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.4M
Investing
$5.2M
Financing
$191.6M
AMLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AMLX vs Biotech Stocks
Amylyx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.